Building patient-derived immune-cell models for testing cancer drugs
Testing cancer drugs on human immune cells requires models that preserve their function outside the body. Short-lived blood-cell preparations limit the time available to compare drug doses, combinations and responses in the laboratory.
EBViome builds living immune-cell models from a small blood sample. Its EBViCells platform keeps B, T and NK cells functional for three weeks, giving pharma and biotech teams time to compare drug doses and combinations in the laboratory.
What stands out about EBViome
Measured immune-cell functional viability in 20 samples from patients and healthy donors using the EBViCells platform.
Joined Shaker by Genopole in 2025, receiving mentoring and incubation support for the EBViome project.
Founded by Shaoni Bhattacharjee, whose research spans EBV-driven cancer biology and postdoctoral work on HIV at Institut Pasteur.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.